Utility of Targeted, Amplicon-Based Deep Sequencing To Detect Resistance to First-Line Tuberculosis Drugs in Botswana.
Qiao WangChawangwa ModongoChristopher AllenderDavid M EngelthalerRobin M WarrenNicola M ZetolaSanghyuk S ShinPublished in: Antimicrobial agents and chemotherapy (2019)
Multidrug-resistant tuberculosis (TB) is an alarming threat, and targeted deep sequencing (DS) may be an effective method for rapid identification of drug-resistant profiles, including detection of heteroresistance. We evaluated the sensitivity and specificity of targeted DS versus phenotypic drug susceptibility testing (pDST) among patients starting first-line anti-TB therapy in Botswana. Overall, we found high concordance between DS and pDST. Lower sensitivity of DS, which targets established high-confidence resistance variants, was observed for detecting isoniazid resistance among HIV-infected patients.
Keyphrases
- drug resistant
- multidrug resistant
- mycobacterium tuberculosis
- hiv infected patients
- acinetobacter baumannii
- cancer therapy
- gram negative
- pulmonary tuberculosis
- single cell
- antiretroviral therapy
- loop mediated isothermal amplification
- klebsiella pneumoniae
- stem cells
- adverse drug
- copy number
- human immunodeficiency virus
- mesenchymal stem cells
- genome wide
- sensitive detection
- replacement therapy
- label free
- high throughput sequencing
- smoking cessation